Menu
Not yet recruiting NCT07499193

Study of Blinking as a Function of Tear Film Quality

No phase Interventional Dry Eye

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blink behaviour.
Who it may be relevant to
Registry conditions: Dry Eye. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Etude Des Clignements en Fonction de la Qualité du Film Lacrymal

Overview

The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye. The main questions are: * Do the results of a New Blink Task reflect tear film stability ? * How are the blink related metrics in relation with each other? Researchers will compare two groups of participants-those without dry eye symptoms and those with dry eye symptoms-to see if blinking measures differ between them and whether these measures relate differently to tear film quality. Participants will: * Answer a questionnaire about dry eye symptoms * Have their visual correction measured (if they wear glasses) * Undergo non-invasive assessments of tear film quality using an imaging device * Complete three types of blink tasks, each repeated three times, including measurements of blinking and of tear film stability

Interventions

  • Other Blink behaviour
    Single intervention

Primary outcome measures

  • Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds and the non-invasive tear film break-up time measured in seconds measured with device IDRA . [Time frame: Day one]
Secondary outcome measures (4)
  • Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds with parameters of dry eye ( tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %)) measured with device IDRA . [Time frame: Day one]
  • Compares the coefficient of variation of the Absolute Maximum Eye Aperture Duration (in %) with the coefficient of variation of the non-invasive tear film break-up time (in %) measured with device IDRA . [Time frame: Day one]
  • Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on two primary outcomes via linear regression model [Time frame: Day one]
  • Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on coefficient of variation of two primary outcomes via linear regression model [Time frame: Day one]

Eligibility criteria

Inclusion criteria

  • Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information sheet and provide free and informed consent
  • Covered by a social security
  • Aged between 18 and 65 years inclusive
  • Binocular near visual acuity ≤ 0.3 LogMAR (≥ 5/10) (corrective glasses accepted)

Exclusion criteria

  • Employees of Essilor International, Luxottica, or GrandVision and their subsidiaries
  • Pregnant or breastfeeding women (Article L1121-5)
  • Individuals deprived of liberty by judicial or administrative decision, or hospitalized without consent under Articles L.3212-1 and L.3213-1, who do not fall under Article L.1121-8, and individuals admitted to a health or social care facility for purposes other than research
  • Adults unable or incapable of giving informed consent (Article L1121-8)
  • Participants currently in an exclusion period from another study
  • Participants deemed unfit to participate by the investigator for any reason that may affect subject safety or study integrity All categories of individuals particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the French Public Health Code).
  • Use of eye drops or ophthalmic solutions within the last 2 hours
  • Wearing contact lenses within the last 48 hours
  • Reported history of severe ocular pathology such as glaucoma, retinitis pigmentosa, diabetic retinopathy, macular involvement, resulting in visual field loss or acuity loss (especially aphakia), except for dry eye (which is not an exclusion criterion)
  • Reported history of eye surgery or trauma to the eye or its adnexa excepted refractive surgery and cataract surgery
  • Reported history of eyelid abnormalities (ptosis)
  • Reported history of neurological deficits, including epilepsy or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders, nystagmus, Parkinson's disease)
  • Reported history of musculoskeletal disorders preventing maintenance of a fixed head position

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

France · 1 center
  • EssilorLuxottica - Neuroscience & Medical Research center — Paris

Identifiers

NCT: NCT07499193 · WS10489 · 2025-A02676-43

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗